Journal ArticleDOI
Cardiovascular safety of tiotropium in patients with COPD.
Reads0
Chats0
TLDR
Tiotropium was associated with a reduction in the risk of all-cause mortality, CV mortality, and CV events, and a 4-year trial in patients with COPD provided an opportunity to better evaluate the cardiovascular (CV) profile of tiotropia.About:
This article is published in Chest.The article was published on 2010-01-01. It has received 173 citations till now. The article focuses on the topics: Tiotropium bromide & Sudden death.read more
Citations
More filters
Journal ArticleDOI
Chronic obstructive pulmonary disease
TL;DR: The main cause is smoking tobacco, but other factors have been identified as mentioned in this paper, such as genetic determinants, lung growth, and environmental stimuli, which is further aggravated by exacerbations, particularly in patients with severe disease.
Journal ArticleDOI
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier,Bettina Hederer,Thomas Glaab,Hendrik Schmidt,Maureen P.M.H. Rutten-van Mölken,Kai M. Beeh,Klaus F. Rabe,Leonardo M. Fabbri +7 more
TL;DR: Results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.
Journal ArticleDOI
Pharmacology and Therapeutics of Bronchodilators
TL;DR: An important step in simplifying asthma and COPD management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control, so the incorporation of once-daily dose administration is an important strategy to improve adherence.
Journal ArticleDOI
Comorbidities of chronic obstructive pulmonary disease.
Andrea Corsonello,Raffaele Antonelli Incalzi,Riccardo Pistelli,Claudio Pedone,Silvia Bustacchini,Fabrizia Lattanzio +5 more
TL;DR: Evidence suggests that systemic inflammation may be the link between COPD and comorbidities, but this issue is still debated.
Journal ArticleDOI
Tiotropium Respimat inhaler and the risk of death in COPD
Robert A. Wise,Antonio Anzueto,Daniel Cotton,Ronald Dahl,Theresa Devins,Bernd Disse,Daniel Dusser,Elizabeth Joseph,Sabine Kattenbeck,Michael Koenen-Bergmann,Gordon Pledger,Peter M.A. Calverley +11 more
TL;DR: Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those of tiotropia HandiHaler at a doses of 18 μg in patients with COPD.
References
More filters
Journal ArticleDOI
Standardization of Spirometry, 1994 Update. American Thoracic Society.
R. Crapo,John L. Hankinson,Charles G. Irvin,Neil R. MacIntyre,K. Z. Voter,Robert A. Wise,Brian L. Graham,C. O'Donnell,P. Paoletti,J. Roca,G. Veigi +10 more
Journal ArticleDOI
A 4-Year Trial of Tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin,Bartolome R. Celli,Stephen Senn,D Burkhart,Steven Kesten,Shailendra Menjoge,Marc Decramer +6 more
TL;DR: Therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1).
Journal ArticleDOI
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.
Alfred P. Fishman,Fernando J. Martinez,Keith S. Naunheim,Steven Piantadosi,Robert A. Wise,Andrew L. Ries,Gail Weinmann,Douglas E. Wood +7 more
TL;DR: Overall, lung-volume-reduction surgery increases the chance of improved exercise capacity but does not confer a survival advantage over medical therapy, although it does yield a survival advantages for patients with both predominantly upper-lobe emphysema and low base-line exercise capacity.
Journal ArticleDOI
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)
Alfred F. Connors,Neal V. Dawson,Charles Thomas,Frank E. Harrell,Norman A. Desbiens,William J. Fulkerson,Peter S. Kussin,Paul E. Bellamy,Lee Goldman,William A. Knaus +9 more
TL;DR: Patients and caregivers should be aware of the likelihood of poor outcomes following hospitalization for exacerbation of COPD associated with hypercarbia, and are advised to report a good, very good, or excellent quality of life.
Journal ArticleDOI
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Nicholas R. Anthonisen,Melissa Skeans,Robert A. Wise,Jure Manfreda,Richard E. Kanner,John E. Connett +5 more
TL;DR: The smoking cessation program was associated with cumulative reduced decline in lung function (FEV1) that was largest in participants who stopped smoking early in the study; inhaled ipratropium produced a small noncumulative increase in FEV1 that disappeared when the drug was withdrawn.